Review Open Access
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. May 25, 2022; 11(3): 113-128
Published online May 25, 2022. doi: 10.5501/wjv.v11.i3.113
Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade
Mohaddeseh Bahmani, Department of Virology, Student Research Committee, Tabriz Univer-sity of Medical Sciences, Tabriz 15731, Iran
Rojin Chegini, Department of Medical Science, Metabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan 81745-33871, Iran
Elham Ghanbari, Department of Medical Science, Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah 67159-59167, Iran
Elham Sheykhsaran, Department of Microbiology, Student Research Committee, Tabriz University of Medical Sciences, Tabriz 15731, Iran
Elham Sheykhsaran, Parisa Shiri Aghbash, Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 15731, Iran
Parisa Shiri Aghbash, Department of Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 15731, Iran
Hamed Ebrahimzadeh Leylabadlo, Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz 15731, Iran
Ehsan Moradian, Department of Medical Science, Medical Faculty, Tabriz University of Medical Sciences, Tabriz 5165665931, Iran
Amir Masoud Kazemzadeh Houjaghan, Department of Internal Medicine, Medical Faculty, Tehran University of Medical Sciences, Tehran 14155-6559, Iran
Hossein Bannazadeh Baghi, Department of Virology, Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz 15731, Iran
ORCID number: Mohaddeseh Bahmani (0000-0002-7438-7653); Rojin Chegini (0000-0001-8505-1728); Elham Ghanbari (0000-0001-6040-1912); Elham Sheykhsaran (0000-0002-9273-433X); Parisa Shiri Aghbash (0000-0001-6733-4556); Hamed Ebrahimzadeh Leylabadlo (0000-0002-3790-9176); Ehsan Moradian (0000-0003-1218-1059); Amir Masoud Kazemzadeh Houjaghan (0000-0001-5456-3835); Hossein Bannazadeh Baghi (0000-0002-2513-5361).
Author contributions: Bahmani M, Bannazadeh Baghi H, and Chegini R contributed to the conceptualization; Bahmani M, Chegini R, and Ghanbari E contributed to writing - original draft; Shiri Aghbash P, and Bannazadeh Baghi H contributed to writing - review and editing; Shiri Aghbash P, Bannazadeh Baghi H, Chegini R, and Sheykhsaran E contributed to the visualization; Leylabadlo HE, Bannazadeh Baghi H, Shiri Aghbash P, Ghanbari E, and Sheykhsaran E contributed to the supervision; Bannazadeh Baghi H and Shiri Aghbash P contributed to the project administration; Moradian E, and Kazemzadeh Houjaghan AM contributed to the language editing.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hossein Bannazadeh Baghi, PhD, Associate Professor, Department of Virology, Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz 15731, Iran. hbannazadeh@tbzmed.ac.ir
Received: December 14, 2021
Peer-review started: December 14, 2021
First decision: February 15, 2022
Revised: March 3, 2022
Accepted: April 28, 2022
Article in press: April 28, 2022
Published online: May 25, 2022
Processing time: 156 Days and 17.1 Hours

Abstract

Since December 2019, a novel coronavirus that represents a serious threat to human lives has emerged. There is still no definite treatment for severe cases of the disease caused by this virus, named coronavirus disease 2019 (COVID-19). One of the most considered treatment strategies targets the exaggerated immune regulator, and interleukin (IL)-6 is a crucial pro-inflammatory mediator. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases show an elevated level of IL-6 related to disease severity. IL-6 activity can be inhibited by the following: IL-6 itself, IL-6 signaling pathways such as Janus kinase and signal transducer and activator of transcription (JAK-STAT), gp130, IL-6R, and downstream activated ILs, such as IL-17 and IL-6 cytokine. Currently, according to these studies and their results, IL-6 blockade with anti-IL-6 or its receptor antibodies such as tocilizumab in COVID-19 is beneficial in severe cases and may reduce the mortality rate. JAK-STAT inhibitors block the cytokine storm by inhibiting several crucial pro-inflammatory mediators such as TNF-α and IL-6 and have shown various results in clinical trials. IL-6 induces IL-17 secretion, and IL-17 is involved in the pathogenesis of inflammatory processes. Clinical trials of anti-IL-17 drugs are currently recruiting, and anti-gp130 antibody is preclinical. However, this agent has shown positive effects in inflammatory bowel disease clinical trials and could be tested for SARS-CoV-2. This study aimed to review the role of IL-6 in the cytokine storm and studies regarding IL-6 and blockade of its inflammatory pathways in COVID-19 to determine if any of these agents are beneficial for COVID-19 patients.

Key Words: Anti-interleukin-6; COVID-19; Inflammation; Interleukin-6; Interleukin-6 receptor; SARS-CoV-2

Core Tip: One of the most considered treatment strategies for severe acute respiratory syndrome coronavirus 2 is targeting the immune response and pro-inflammatory cytokines such as interleukin (IL)-6. Patients with severe acute respiratory syndrome coronavirus 2 show elevated levels of IL-6, which is related to disease severity. Current studies have shown that IL-6 blockade by anti-IL-6 or its receptor antibodies such as tocilizumab is beneficial in severe cases and may reduce the mortality rate. Moreover, the combination of anti-inflammatory agents is more effective than single therapy.



INTRODUCTION

In December 2019, an epidemic of secretive pneumonia which started in Wuhan city, Hubei province, China, quickly spread to many other countries and finally resulted in a pandemic[1]. The causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a single-stranded enveloped RNA virus belonging to Nidovirales and the family Coronaviridae. The analysis of SARS-CoV-2 genome structure has shown that this virus is related to the beta-coronavirus genus, containing bat SARS-identical coronavirus and two previous invasive coronaviruses Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and SARS-CoV[2]. Universally, as of September 2021, there have been 226,844,344 recognized cases of SARS-CoV-2, including 4,666,334 victims[3]. The disease caused by the novel coronavirus, coronavirus disease 2019 (COVID-19), is similar to these previous viruses, which is mainly pulmonary disease[4], and all of them have a zoonotic origin. In addition to pulmonary involvement, various organs such as the kidney, gastrointestinal system, nervous system, liver, and coagulation system, may be targets of the virus, leading to serious complications such as acute kidney injury (AKI), acute pulmonary failure, and disseminated intravascular coagulation (DIC) that may lead to death[5]. Currently, this virus is a serious global concern with enormous social and economic damage to societies worldwide[6].

Moreover, the fatality rate is high in severe cases[7]. At present, we do not have any definite treatment for severe cases of this disease, and the management of severe SARS-CoV-2 patients is still challenging. Therefore, various treatment options have been assumed according to the different levels of viral pathogenesis, including viral entry, replication, and effects of the virus on target cells. The anti-viral agent remdesivir is the only treatment with Food and Drug Administration (FDA) approval for this disease, and dexamethasone is the only drug to reduce mortality in hospitalized patients with decreased oxygen saturation but not in others[8]. However, the World Health Organization (WHO) has suggested mortality trials for some repurposed anti-viral drugs, including lopinavir, interferon beta 1a (INF-β1a), and hydroxychloroquine in hospitalized patients with SARS-CoV-2[9].

In this regard, IL-6 is known as a crucial inflammatory mediator with essential roles in the pathogenesis of inflammatory diseases in addition to several chronic disorders such as diabetes mellitus[10]. This cytokine is widely expressed by different immune cells and affects immune function[11]. Thus, the disease has a wide range of symptoms. Clinical deterioration in COVID-19 is mainly due to the effects of inflammatory cytokines such as IL-1, IL-6, IFN-α, and tumor necrosis factor (TNF) that are increased in the cytokine storm phase, and the role of immune cells including neutrophils[12-15]. In this process, when a neutrophil encounters a pathogen, the extensive release of cytokines such as IL-1 and IL-6 may become harmful to the body and lead to multi-organ damage[13]. In this rationale, targeting the cytokine release syndrome (CRS) symbolizes a possible therapeutic goal in managing SARS-CoV-2 related cytokine storms and IL-6[16].

In this study, we aim to review the role of IL-6, the rationale of IL-6 blockade in COVID-19, and the results of recent studies on this topic to determine whether any available anti-IL-6 agents or any other drugs with the ability to inhibit inflammatory pathways induced by this cytokine have shown efficacy in improving patient prognosis in SARS-CoV-2 infection.

STUDY METHOD

PubMed, Google Scholar, Scopus, and the Web of Science were searched with the following keywords or their combinations, without any time limits: COVID-19, IL-6, IL-6 receptor, SARS-CoV-2, anti-IL-6, Inflammation. Related articles of any type were selected and reviewed. Extracted information included: SARS-CoV-2 pathophysiology and characteristics, IL-6 activities in the immune system and associated pathways, studies focused on the concept of anti-IL-6 antibodies in the treatment of COVID-19, and other methods of IL-6 inhibition [Janus kinase and signal transducer and activator of transcription (JAK-STAT) inhibition and anti-IL-17 therapies] and are discussed further.

SARS-COV-2 PATHOPHYSIOLOGY AND CHARACTERISTICS

In the last two decades, the third most common coronavirus to cause a pandemic of acute respiratory disease in humans is SARS-CoV-2. These viruses enter the body through respiratory aerosols and are attached to the nasal or paranasal epithelial cells[17]. Angiotensin-converting enzyme 2 (ACE-2) is the major receptor for these viruses to enter host cells, which is expressed in nasal epithelial cells[18,19].

The virus, along with the infection of ciliated cells in the airways, undergoes local replication and dissemination. This stage lasts a few days, and a slight immune response is produced during this process. Despite having a low viral load at this time, infected individuals are highly contagious, and the virus can be identified following a nasal swab[20].

Virus entry into the host cell

Through its spike (S) protein, the virus enters the host cell by binding to ACE-2 on the cellular surface. Transmembrane serine protease 2 (TMPRSS2), then mediates S protein cleavage, and the virus enters the cell[21]. A high virus infectivity rate is associated with mutations in the binding domain of the receptor and the acquisition of a furin cleavage site in the S protein. The association of the virus with ACE-2 can decrease anti-inflammatory function and increase angiogenic activity[22]. The virus migrates from the nasal epithelium to the upper respiratory tract within the conducting airways[23]. The disease presents various signs and symptoms such as fever and dry cough due to involvement of the upper respiratory tract[24].

At this stage, a higher immune response occurs due to the virus-infected cells and results in the secretion of C-X-C motif chemokine ligand 10 (CXCL-10) and interferons (IFN-β and -λ). As a result of the sufficient immune response to control the spread of infection, the majority of patients do not advance beyond this point[25]. About one-fifth of infected individuals advance to this point and may experience severe symptoms. The virus, via the host receptor ACE-2, targets alveolar epithelial cells type 2 and continues to undergo replication to create more and more viral nucleocapsids[26].

Many distinct cytokines and inflammatory markers are now produced by virus-laden pneumocytes such as ILs (IL-1, IL-6, IL-8, and IL-12), tumor necrosis factor-alpha (TNF-α), IFN-λ and IFN-β, monocyte chemoattractant protein-1 (MCP-1), CXCL-10, and macrophage inflammatory protein-1 alpha (MIP-1α). This 'cytokine storm' serves as a chemoattractant to neutrophils, CD4 helper, and CD8 cytotoxic T cells, and these cells then become sequestered in the pulmonary tissue[27,28]. In addition to being crucial in fighting the virus, these cells cause inflammation and damage to the lungs and other organs. The host cell undergoes apoptosis and releases new viruses, which will then infect the neighboring type 2 alveolar epithelial cells in the same way. Diffuse trauma to the alveoli eventually results in an acute respiratory syndrome and finally respiratory distress, owing to the recurrent injuries triggered by the sequestered immune cells and viral replication, contributing to the annihilation of both type 1 and type 2 pneumocytes[29,30].

COVID-19 spreads mainly by the transmission of respiratory droplets from person to person and occurs when someone is in close contact with an infected individual who is coughing or sneezing violently. This occurs as the host's mucosal surfaces, i.e., the eyes, nose, and mouth, are exposed to the infected respiratory droplets[31]. Virus transmission may also occur by fomites, such as bedsheets, towels, kitchen utensils, thermometers, and stethoscopes, used by or used on the infected person. Airborne transmission of COVID-19 can occur especially in situations where aerosol-generating procedures are conducted, i.e., endotracheal intubation, bronchoscopy, open suction, oxygen nebulization, bronchodilators, or steroids, ventilation using a bag and mask, tracheostomy, and cardiopulmonary resuscitation[32]. In this way, the incubation time for SARS-CoV-2 (between the onset of symptoms and exposure to the virus) is about 5 to 6 d. However, it can be up to 14 d. During this time, also known as the 'pre-symptomatic' phase, the affected individual can be contagious and transmit the virus to the healthy population[33,34]. The most frequent symptoms include fever, muscle aches, shortness of breath, malaise, and a dry cough.

While patients can remain asymptomatic or develop a mild, moderate, or severe illness, gastrointestinal manifestations such as stomach pain, vomiting, and loose stools can also occur. Many of the complications seen in SARS-CoV-2 infected individuals are attributed to the CRS[35,36].

Cytokine storm

The cytokine storm was historically referred to as an influenza-like syndrome that occurred during systemic diseases such as sepsis and after immunotherapies such as Coley’s toxins. Yersinia pestis (causative agent of plague or black death) infection has led to extreme pandemics; it induces alveolar macrophages to produce disproportionate quantities of cytokines, resulting in the cytokine storm and has subsequently caused massive pandemics[37]. An intensive inflammatory response and fast release of various cytokines (such as TNF-α-1, 2, IL-6, and IFN-γ) to the circulation are activated by pathogen infection (Figure 1). Patients with viral infections are especially vulnerable to acute respiratory failure due to the cytokine storm[38]. For instance, in other coronaviruses (SARS and MERS), cytokine cascades and low lymphocytes are positively linked to the course and severity of the disease. Recent experiments have supported this conclusion in most cases of SARS-CoV-2, indicating low lymphocyte counts and heightened levels of inflammatory mediators[12,39]. Furthermore, it has been shown that pro-inflammatory cytokines such as IL-6 play an essential role in the progression of COVID-19.

Figure 1
Figure 1 The mechanism of the inflammatory storm. ① Antigen presenting; Dendritic cells activate T-cells by processing the antigen and delivering it to these cells; ② Start reproducing; Native T cells become activated by receiving antigens from dendritic cells; ③ A significant quantity of cytokines is secreted during the activation of T cells. These cytokines can activate B cells, macrophages, and NK cells; ④ Activated T cells also release cytokines and further activate macrophages, B cells and NK cells; ⑤ Cytokines secreted; These activated cells, in turn, lead to the secretion of inflammatory and pro-inflammatory cytokines; the resulting cytokine storm leads to the development of clinical signs of infection.
IMMUNE SYSTEM AND ROLES OF IL-6

IL-6 is a soluble mediator with various functions in the immune system[40]. For example, controlling the differentiation and migration of immune cells, apoptosis of target cells[41], and assembly of acute-phase proteins such as C-reactive protein (CRP), haptoglobin, and fibrinogen. In contrast, IL-6 reduces the production of other proteins such as albumin. Human IL-6 comprises 212 amino acids (28-amino-acid signal peptide), and its controlling gene is located on chromosome 7p21[40]. This interleukin contributes to hypothalamic-pituitary-adrenal axis regulation and glucose homeostasis. It induces the differentiation of T-helper cells, which secrete IL-17. These cells are related to the pathogenesis of chronic inflammatory diseases[42]. IL-6 is produced in the immune system by various cells including endothelial cells and contributes to the pathogenesis of chronic inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and systemic lupus erythematosus[41]. This cytokine acts by binding to its receptor on the target cells that consist of CD126 (IL-6 Receptor-α) and glycoprotein 130 (gp130). Therefore, it activates signaling pathways such as JAK-STAT[43] and mitogen-activated protein kinase[11]. Conformational alterations in the gp130 cytoplasmic domain when IL-6 binds to the IL-6 receptor induces activation of JAK-STAT[43], and JAK-STAT signaling pathway activation leads to cytokine release[44]. However, these signaling pathways downregulate IL-6 expression[11].

While the membrane-bound receptor (IL-6Rα) is expressed only on the surface of a small number of cells such as leukocytes and hepatocytes (known as IL-6 classic signaling), IL-6 can affect many other cells through its soluble receptor (sIL-6Rα). It was recently discovered that endothelial cells also express IL-6R. This receptor forms a complex with IL-6 that binds to gp130. This complex then mediates a signal known as IL-6 trans-signaling through which pro-inflammatory responses are mainly mediated. In contrast, the classic signaling pathway is related to anti-inflammatory pathways[41]. Furthermore, IL-6 is produced by the innate immune cells after encountering a pathogen and is critical in the body's defense against the respiratory syncytial virus and influenza virus in the early infection phases[45]. However, in CRS, IL-6 and IL-5 can induce coagulation cascade and complement system over-activation, capillary leakage, hypotension, and myocardial dysfunction[46].

In severe SARS-CoV-2 infection, high levels of pro-inflammatory mediators are present, such as IL-6. Although one study showed that monocytes were a source of IL-1β and IL-8, the exact source of IL-6 remains unclear[47]. In the presence of immune dysregulation, in addition to a non-sufficient anti-viral response, there is also a continuous secretion of pro-inflammatory mediators such as IL-6 that resembles the macrophage activation syndrome and lead to multi-organ damage[45]. Also, in COVID-19, multifocal interstitial pneumonia is the chief reason for pulmonary failure and death. In this process, there are inflammatory infiltrates in the interstitial tissue of the lungs, which lead to alveolar damage[48]. These infiltrates consist of mononuclear cells that will be induced after the pro-inflammatory pathways are activated by trans-signal transduction of IL-6[45]. In this way, one study showed that patients with high levels of ACE-2 expression experience more severe tissue damage by IL-6 and the cytokine storm after infection with SARS-CoV-2. These individuals also have a suppressed immune system to fight against the virus[7]. In summary, IL-6 is crucial in both pro-inflammatory and anti-pathogen responses, and trans-signaling is the critical pathway of inflammatory processes conducted by IL-6. A diagram of the significant roles of IL-6 and its location in the immune cascade is summarized in Figure 2.

Figure 2
Figure 2 Interleukin-6 in the immune system. IL: Interleukin; JAK-STAT: Janus kinase and signal transducer and activator of transcription.
DRUGS AVAILABLE TO INHIBIT IL-6 ACTIVITY

According to the signaling pathways induced by IL-6 and its components, IL-6 activity can be inhibited by the following: IL-6 itself, IL-6 signaling pathways such as JAK-STAT, gp130, IL-6R, or the IL-6/sIL-6R complex[49]. Two main drugs in the class of IL-6 receptor blockers are tocilizumab (TCZ) and slumab, which are FDA approved monoclonal antibodies for rheumatoid arthritis, and TCZ is also approved for juvenile idiopathic arthritis (JIA) and giant cell arteritis[50].

TCZ blocks both soluble and membrane-bound receptors and accordingly blocks signal transduction via JAK-STAT[51]. JIA, a chimeric antigen receptor (CAR)-T cell-induced CRS, giant cell arteritis, rheumatoid arthritis, and Still’s disease are examples of the conditions in which TCZ has been used to control the disease[52]. Siltuximab is an anti-IL-6 agent that has shown more effectiveness than TCZ in some aspects, and although it is not FDA approved, it is used in refractory CRS cases. Data regarding Siltuximab in COVID-19 are currently restricted[46].

The specific gp130FC named Olamkicept specifically blocks the trans-signaling pathway. In animals, it showed more effectiveness in controlling the hyper-inflammatory status due to sepsis than anti-IL-6 antibodies. Significantly, it did not impair the anti-inflammatory responses of IL-6 via classic signal-transduction[45]. JAK-STAT inhibition is another option. Some of these agents are currently on COVID-19 clinical trials, such as ruxolitinib. A list of these drugs is shown in Table 1.

Table 1 Drugs with anti-interleukin-6 activity and their side effects with examples of clinical trials in coronavirus disease 2019.
Ref.
SARS-CoV-2 clinical trials on Clinicaltrial.gov
Side effects
Examples
Category
[93]NCT04661527, NCT04315298, NCT04357808, NCT04386239, NCT04341870, NCT04359901, NCT04380519Cytopenia, intestinal perforation, Hypersensitivity, immunosuppression, and the possibility of infections, impairment of liver enzymes SarilumabThe anti-receptor of IL-6
[94,95]NCT04445272, NCT04331795, NCT04346355, NCT04320615, NCT04356937, NCT04403685, NCT04339712Intestinal perforation, Hypersensitivity, immunosuppression, and the possibility of infections, acute liver dysfunction, demyelination, cardiac injury, and hepatitisTocilizumab
[96]NCT04322188, NCT04329650, NCT04330638Hypersensitivity disorders, intestinal perforation, risk of infectionsSiltuximabAnti-IL-6
[97]-Preclinical; in a phase 2 trial of IBD, it showed effectiveness. Patients in this study who were treated with the drug had hypersensitivity skin reactions and respiratory infections. In animal studies, it did not show serious immunosuppressionOlamkiceptSpecific gp130fc
[98]NCT04358614, NCT04401579, NCT04640168, NCT04381936 (RECOVERY Trial), NCT04320277Increased risk of infections including reactivation of latent infections, lymphoproliferative disorder, cytopenia, liver enzymes disturbances, clot formation, intestinal perforationsBaricitinibJAK inhibitors
[99]NCT04348071, NCT04377620, NCT04362137, NCT04366232Skin malignancy, exacerbation with drug discontinuation, cytopenia, and immunosuppression, increased risk of infectionRuxolitinib
EXPERIENCE OF IL-6 BLOCKADE IN COVID-19

The cytokine storm is associated with disease intensity in SARS-CoV-2, as also shown in SARS-CoV-1 and MERS-CoV. Although the reports from different studies focused on IL-6 blockade in COVID-19 are inconsistent, it was first shown to reduce the mortality rate in critically ill patients[53].

Considering the presence of lymphopenia in SARS-CoV-2 patients, administration of immunosuppressive agents might increase the risk of secondary fungal or bacterial infections[54]. In a previous study, TCZ induced necrotizing fasciitis and candidemia[55]. Accordingly, the exact place for immunosuppression and anti-IL-6 agents in COVID-19 is crucial. The possible effects of TCZ on management of the COVID-19 related cytokine storm first originated from observational studies that showed it to be effective in the clinical improvement of COVID-19 patients[56]. In a recent clinical trial, the effect of a single dose of 8 mg/kg TCZ administration via the intravenous route in addition to the standard of care in the management of COVID-19 was investigated. In this study, 46 adult patients who were positive for SARS-CoV-2 and had multifocal interstitial pneumonia on imaging studies were enrolled soon after showing clinical worsening. The drug was influential in the clinical improvement of severely ill patients and patients in the early clinical worsening state. However, it did not show significant efficacy in reducing the mortality rate and was accompanied by adverse effects[48].

According to a recent observational study, having an IL-6 level of more than 30 pg/mL is related to the disease severity and need for respiratory support in COVID-19 patients. This study showed the positive effects of TCZ in patients with higher IL-6 levels at baseline, but no positive trends were seen in the group with low IL-6 levels[51].

A recent case series showed the efficacy of subcutaneous TCZ in three severely ill COVID-19 patients in reducing inflammatory-related indices and improving the clinical condition[57]. The results of a prospective phase two cohort study (TOCIVID-19) showed that TCZ effectively reduced the mortality rate at 30 d, especially in severe patients who did not require mechanical ventilation. This effect was independent of corticosteroids and was not accompanied by significant adverse events[58].

One of the concerns regarding the use of anti-immune drugs in SARS-CoV-2 is that they may interfere with the proper immune response to the virus. Cytokines, especially IL-6, play a significant role in the host's fight against viruses through the humoral and cellular responses by affecting helper and cytotoxic T cells. Accordingly, a cohort study conducted in Spain found that these drugs do not pose a problem in the body's fight against the virus. Although the study found that patients treated with anti-cytokines had a longer viral clearance time, they initially had higher virus levels, and their disease was more severe[59]. A preprint study that showed an unexpected increase in inflammatory mediators after TCZ administration supports the fact that IL-6 blockade alone may not be effective in the management of COVID-19[60]. Recently, two studies showed a transient elevation in the D-dimer level in SARS-CoV-2 patients receiving TCZ[61,62]. A recent meta-analysis also demonstrated that IL-6 blockade alone does not lower the mortality rate, although it may effectively reduce the risk of respiratory failure in hospitalized patients[63]. According to another study, administration time is another crucial factor, and treatment with TCZ ten days after disease onset is more beneficial[64]. In contrast, other studies, including the RECOVERY trial, have shown that early administration of TCZ in severe cases before intensive care unit (ICU) admission and the need for mechanical ventilation is effective in reducing the mortality rate,[65,66] and when the patient requires mechanical ventilation, it will not have much effect[66,67]. In general, different methods and inclusion criteria in studies do not result in the same conclusions. A list of recent studies in this regard is summarized in Table 2. According to some clinical trials, TCZ, when added to a corticosteroid, markedly reduces the mortality rate compared with corticosteroids (CSs) alone. Treatments that include agents to target more ILs in addition to IL-6 have more efficacy than only IL-6 blockade[63,68]. IFN-γ, granulocyte-macrophage colony-stimulating factor (GM-CSF), TNF, IL-1, and IL-8 are the primary inflammatory mediators that could be targeted in CRS. IL-1 is proximal to IL-6 in the inflammatory cascade, and its blockade has recently been considered. A recent study compared the effectiveness of IL-1 and IL-6 blockade with the standard of care, and it was observed that IL-1 inhibition is more effective in reducing the mortality rate, while positive effects of IL-6 antibodies were restricted to a group of severely ill patients with high CRP levels[50]. Another clinical trial of TCZ in COVID-19 patients with a hyperinflammatory state also stopped recruiting as it failed to reach its primary endpoints (improving the patient's clinical status or reducing the mortality rate)[69]. In general, despite the effect that IL-6 blockade has on the suppression of inflammation, it cannot completely control inflammation as it does not affect the distal inflammatory pathways[70]. However, in severe and critical SARS-CoV-2 patients with a hyperinflammatory state, IL-6 blockade with monoclonal antibodies seems to be effective in reducing the mortality rate, reducing the risk of mechanical ventilation, and improving the clinical condition[67,71-74]. Although all of these studies have been performed in adult patients, the effect of TCZ in the treatment of COVID-19 in children is also being investigated in the RECOVERY trial[67].

Table 2 List of recent clinical trials and observational studies regarding interleukin-6 blocker monoclonal antibodies in severe acute respiratory syndrome coronavirus 2.
Study design
Inclusion criteria
Interventions
Number of patients
Results
Ref.
Observational retrospectiveSevere SARS-CoV-2 positive ICU admitted patients, with or without respiratory failureSingle 400 mg TCZ dose, without antimicrobialprophylaxis55 severe patients were treated,Compared with 41 untreated (non-severe) patientsLower mortality rate among treated patients against more disease severity, with no serious side effects and no significantly different increased infection rates[53]
Quasi-experimentalSARS-CoV-2 positive patients with respiratory failure or a need for supplemental oxygen, with clinical or laboratory signs of acute inflammationComparing CSs, and TCZ (8 mg/kg up to 800 mg/dose up to 3 doses)33 patients in the TCZ group and 60 in the CS group.These drugs both reduced the need for supplemental oxygen and ICU stay to the same level, but in the CS group the survival rate was higher, use of TCZ was safe[100]
CohortCOVID-19 patients with respiratory failure and acute inflammatory laboratory findings, such as an elevated CRP levelAnakinra: 5 mg/kg BD until clinical improvement; TCZ: 400 mg single dose, repeated according to the clinical condition; Sarilumab: 400 mg single dose62 patients received IL-1 blocker and 55 IL-6 blocker (26 sarilumab and 29 TCZ) (severe patients); 275 without IL blockade (standard of care only)IL-6 blockade had only limited effectiveness in individuals with high concentrations of CRP, but IL-1 blockade reduced the mortality rate in all patients[50]
Retrospective observationalSevere patientsTocilizumab use was compared with standard of care in ICU patients78 severe patients received tocilizumab and were compared with 112 severe patients who received standard of carePatients on tocilizumab had a longer hospital and ICU stay and more costs with no reduction in the mortality rate[101]
Retrospective observationalSevere SARS-CoV-2 patients with respiratory failureTCZ 8 mg/kg30 severe patients with respiratory failure who received TCZ were evaluated for inflammatory markers and clinical condition after treatmentPatients had better oxygenation and inflammatory markers decreased after treatment with TCZ[102]
Randomized, double-blindclinical trialHospitalized patients without respiratory failure and mechanical ventilation, but with decreased SpO2 in room air 8 mg/kg up to 800 mg, TCZ; One-two doses249 TCZ; 128 SOCLikelihood ratio of; serious adverse outcomes were significantly lower in the treatment group; But no reduction in all-cause mortality rate[8]
Clinical trialModerate and severe patients according to the clinical status, with higher IL-6 levels, neither ICU admitted nor on mechanical ventilationTCZ 400 mg; Single-dose29 patients were treated with TCZ and 32 received standard of care onlyTCZ was safe but did not show any significant difference in clinical improvement[103]
Cross-sectional, observationalSevere patients with high levels of inflammatory markersTCZ 4 mg/kg54 patients were treated with TCZSignificant reduction in neutrophil count and CRP[104]
Clinical trialPatients with hyper-inflammatory state and acute respiratory failureTCZ 8 mg/kg (up to 800 mg); After 12 h: second dosage66 severe patients received TCZ and were compared with 60 patients who received standard of careNot effective in decreasing the risk of disease deterioration[105]
Open-label clinical trialProven SARS-CoV-2 infection, with the need for respiratory support and recent worsening in the clinical conditionTCZ 8 mg/kg46 moderate and severe patients were treated with TCZTreatment improved respiratory function[48]
Clinical trialHigh levels of IL-6Moderate and severe disease severityTCZ 400 mg (second dosage after 24h)34 patients were treated and 31 were notTreatment with TCZ improved respiratory condition without reducing the mortality rate[106]
Clinical trialSevere and critical patientsSarilumab 400 mgTotal = 416 (Sarilumab 400 mg, n = 173; Placebo, n = 84; Sarilumab 200 mg, n = 159); Primary analysis between 194 severely ill patients who needed respiratory supportDid not meet the primary and secondary endpoints in improving disease progression and the study stopped further recruitmentNCT04315298 [107,108]
Randomized, double-blindclinical trialSevere patients with decreased SpO2 without supplemental oxygenTCZ 8 mg/kg up to 800 mg2:1 Placebo+ Standard of care (151); TCZ+ SOC (301)No significant benefits on mortality rate or clinical improvement, but a positive effect on hospitalization duration was observed with no significant side effects compared with the control groupNCT04320615 [109]
Retrospective cohortSARS-CoV-2 positive patients with severe pneumoniaTCZ one to two doses, 400–800 mg every 12 hn = 62 treated, n = 86 untreatedTreated patients showed significantly lower leukocytosis compared to the control group after 14 d. D-dimer and ferritin initially increased and then decreased in the treated group. The mortality rate at 28 d was statistically lower in the TCZ group. A longer hospital stay was shown in these patients although this was not statistically significant. Ten patients developed an infection during hospitalization[62]
Retrospective cohortModerate to severe SARS-CoV-2 patientsOne to two doses of TCZ 8 mg/kg170 treated; 655 untreatedClinical improvement was significantly better in the treatment group compared with the control group. A significant reduction in the mortality rate at 21 and 28 d was found in patients with respiratory failure and patients with IL-6 levels above 100 pg/mL[110]
Randomized clinical trialCritical patients with respiratory failure who were admitted to the ICU TCZ one to two doses (8 mg/kg); Sarilumab (a single dose of 400 mg); Other interventions: Anakinra and interferon beta-1a350 on TCZ; 45 on sarilumab; 1136 on another immunomodulator; 397 on no immunomodulationIL-6 blocking agents were effective in reducing the mortality rate. When added to corticosteroids, this effect was stronger compared with IL-6 blockade aloneNCT02735707 [74]
Randomized, controlled, open-label clinical trialCOVID-19 patients with worsening clinical status or with high CRP levels after 21 d of the first randomization to dexamethasone, lopinavir–ritonavir, hydroxychloroquine, azithromycin, or colchicine or convalescent plasma or a combination of two anti-SARS-CoV-2 spike protein antibodies (REGN-COV2) or aspirinA single dose of TCZ according to the patient’s weight2022 received TCZ; 2094 received standard of careTCZ group had a significantly lower mortality rate, need for mechanical ventilation, and higher chance of hospital discharge at day 28. This effect was similar in patients randomized less than or more than two days from hospitalization. In patients who were on mechanical ventilation at the time of drug administration, this drug had no significant effect on improving prognosis[67]
Randomized, double-blindclinical trialSevere COVID-19 patientsSarilumab 200 or 400 mg, single dosen = 153 sarilumab 400 mg, n = 141 sarilumab 200 mg, n = 75 placeboNo significant effectiveness was found in the treatment groups compared with the control group[111]
Randomized, double-Blind, placebo-controlled trialPatients with COVID-19 in a hyper-inflammatory stateTCZ 8 mg/kg up to 800 mgTCZ (n = 161); Placebo (n = 81) + standard of careNo significant benefits from early TCZ administration in COVID-19 were observed[112]

To date, several clinical trials have failed to show the efficiency of TCZ in COVID-19 treatment. However, the RECOVERY trial and some other clinical trials showed positive results[67,75,76]. Although meta-analysis had previously demonstrated an 11% reduction in 28-d mortality following TCZ administration in patients with severe SARS-CoV-2 infection, this reduction was significant when the results of the RECOVERY trial were added[67]. In conclusion, this drug can effectively improve the prognosis in extreme cases.

TCZ inhibits both classic and trans-signal transduction through IL-6, thus interfering with this cytokine's anti- and pro-inflammatory functions. As mentioned previously, IL-6 signaling pathways involve the JAK-STAT that could be targeted with drugs such as ruxolitinib, a JAK 1 and 2 inhibitor. This drug lowers the levels of IL-6 and is currently being evaluated for SARS-CoV-2 and had positive effects in one study[77]. However, RUXCOVID, a phase 3 clinical trial of ruxolitinib, revealed no significant efficacy in reducing the death rate and serious complications[78]. Another JAK inhibitor is baricitinib. A recent clinical trial (ACTT2) that evaluated baricitinib in hospitalized patients with SARS-CoV-2 infection indicated that it reduced the recovery time when added to remdesivir, compared with remdesivir alone[79,80]. Another study also investigated the potency of the anti-myeloproliferative agent ruxolitinib and included the patients requiring supplementary oxygen but not with respiratory failure. This study found that inflammatory mediators significantly reduced after ruxolitinib administration which also improved clinical conditions. These successes were not accompanied by any severe effects[81]. Another effect of JAK inhibitors in hampering the cytokine storm is related to TNF, the other crucial inflammatory mediator in the cytokine storm that uses JAK signaling and can be inhibited by JAK inhibitors. A recent study evaluated the concurrent administration of an IL-1 blocker antibody and ruxolitinib in critical patients with SARS-CoV-2. The preliminary report of this study demonstrated that this combination was beneficial in clinical improvement, and the lymphocyte count increased after this treatment[82]. In addition, no treatment-related severe complications were observed. Tofacitinib is another JAK inhibitor that was shown to reduce adverse outcomes and mortality in COVID-19 patients in a previous retrospective cohort study[83]. Another exciting intervention for IL blockade with positive effects in patients on ECMO in previous research was extracorporeal cytokine adsorption which showed a significant decrease in IL-6 in treated patients[84,85]. Other agents with anti-IL-6 properties have not yet been entered in clinical trials of COVID-19. However, targeting the trans-signaling pathway seems more efficient than non-specific IL-6 blockade with monoclonal antibodies.

IL-6 INDUCES TH17 LINEAGE DIFFERENTIATION

Th17 is related to inflammatory processes. As mentioned in Figure 2, when the IL-6-sIL-6R complex reaches CD4+ T cells, it causes them to differentiate into Th17 cell lineage. This action is mediated through the JAK-STAT signaling pathway (IL-6 recruits JAK 1 and 2). These cells can secrete IL-17, 21, and 22 and GM-CSF, and therefore contribute to the pathogenesis of inflammatory processes and chronic diseases. Viral diseases also promote Th17 related responses, and severe cases show higher Th17-related cytokines. Accordingly, Th17 blockade seems to be another way to fight against COVID-19, especially in extreme cases. One study showed that fedratinib reduced Th17 related cytokines in mouse models. Fedratinib is a JAK 2 inhibitor[86].

It was shown that the Th17 subgroup of T cells is increased relative to the other subgroups in severe COVID-19 cases. The role of these cells in SARS-CoV-2 patients with lung injuries has been revealed. Drugs with anti-IL-17 activities include ixekizumab, secukinumab, and brodalumab, and they are used in moderate to severe cases of psoriasis[87,88]. Ixekizumab is an anti-IL-17 antibody and is currently being evaluated in a COVID-19 clinical trial. Inclusion criteria in this study are those with high serum levels of IL-6 and not admitted to the ICU[89]. When IL-17 is secreted from Th17 cells, it causes target cells to produce inflammatory mediators, including IL-6, TNF-α, chemokine C-C motif 2 (CCL2), and IL-1β. These procedures lead to CRS and clinical worsening in SARS-CoV-2[87]. IL-17 is also related to the cutaneous manifestations of COVID-19[90]. However, recent evidence has shown undetectable quantities of IL-17A expression in COVID-19 patients[91]. In a previous study, secukinumab, an anti-IL-17A selective antibody, resulted in clinical improvement in severe SARS-CoV-2 patients[92].

CONCLUSION

According to the above-mentioned data, IL-6 blockade alone with anti-IL-6R monoclonal antibodies has no significant benefits in improving the prognosis of patients, except for those in a critical condition and in the hyper-inflammatory state before mechanical ventilation. Many factors are related to a patient's response to IL-6 blockade, such as baseline IL-6 level and disease severity. It may also be associated with some worrying side effects. According to recent data, a combination of anti-inflammatory agents is more effective than any one agent alone. Other ways to inhibit IL-6, such as a selective trans-signaling pathway and JAK-STAT inhibition, should be investigated further.

ACKNOWLEDGEMENTS

The authors would like to thank the Clinical Research Development Unit and Tabriz University of Medical Sciences Faculty of Medicine for providing the expertise that greatly assisted in this work.

Footnotes

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Virology

Country/Territory of origin: Iran

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

P-Reviewer: Singh AK, India; Wang H S-Editor: Ma YJ L-Editor: Webster JR P-Editor: Ma YJ

References
1.  Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020;83:217-220.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 878]  [Cited by in F6Publishing: 699]  [Article Influence: 174.8]  [Reference Citation Analysis (0)]
2.  Shahrajabian MH, Sun W, Cheng Q. Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. Hum Vaccin Immunother. 2021;17:62-83.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 7]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
3.  World Health Organization  WHO Coronavirus (COVID-19) Dashboard. [cited September 19, 2021] Available from: https://covid19.who.int/.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Castelnovo L, Tamburello A, Lurati A, Zaccara E, Marrazza MG, Olivetti M, Mumoli N, Mastroiacovo D, Colombo D, Ricchiuti E, Vigano' P, Paola F, Mazzone A. Anti-IL6 treatment of serious COVID-19 disease: A monocentric retrospective experience. Medicine (Baltimore). 2021;100:e23582.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39]  [Cited by in F6Publishing: 32]  [Article Influence: 10.7]  [Reference Citation Analysis (0)]
5.  Sarkesh A, Daei Sorkhabi A, Sheykhsaran E, Alinezhad F, Mohammadzadeh N, Hemmat N, Bannazadeh Baghi H. Extrapulmonary Clinical Manifestations in COVID-19 Patients. Am J Trop Med Hyg. 2020;103:1783-1796.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 54]  [Cited by in F6Publishing: 48]  [Article Influence: 12.0]  [Reference Citation Analysis (0)]
6.  IHME COVID-19 Forecasting Team. Modeling COVID-19 scenarios for the United States. Nat Med. 2021;27:94-105.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 297]  [Cited by in F6Publishing: 247]  [Article Influence: 82.3]  [Reference Citation Analysis (0)]
7.  Bao Z, Wang LJ, He K, Lin X, Yu T, Li J, Gong J, Xiang G. High expression of ACE2 in the human lung leads to the release of IL6 by suppressing cellular immunity: IL6 plays a key role in COVID-19. Eur Rev Med Pharmacol Sci. 2021;25:527-540.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 2]  [Reference Citation Analysis (0)]
8.  Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, Cameron ML, Garcia-Diaz J, Chávez V, Mekebeb-Reuter M, Lima de Menezes F, Shah R, González-Lara MF, Assman B, Freedman J, Mohan SV. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;384:20-30.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 912]  [Cited by in F6Publishing: 886]  [Article Influence: 295.3]  [Reference Citation Analysis (0)]
9.  WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384:497-511.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1601]  [Cited by in F6Publishing: 1682]  [Article Influence: 560.7]  [Reference Citation Analysis (0)]
10.  Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16:448-457.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1352]  [Cited by in F6Publishing: 1392]  [Article Influence: 154.7]  [Reference Citation Analysis (0)]
11.  Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B, Vo A. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade. Transplantation. 2017;101:32-44.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 154]  [Cited by in F6Publishing: 194]  [Article Influence: 27.7]  [Reference Citation Analysis (0)]
12.  Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Front Immunol. 2020;11:1708.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 768]  [Cited by in F6Publishing: 691]  [Article Influence: 172.8]  [Reference Citation Analysis (0)]
13.  Hemmat N, Derakhshani A, Bannazadeh Baghi H, Silvestris N, Baradaran B, De Summa S. Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study. Front Genet. 2020;11:641.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 60]  [Cited by in F6Publishing: 63]  [Article Influence: 15.8]  [Reference Citation Analysis (0)]
14.  Hemmat N, Asadzadeh Z, Karim-ahangar N, Alemohammad H, Najafzadeh B, Derakhshani A, Baghbanzadeh A, Bannazadeh Baghi H, Javadrashid D, Najafi S, Gouilh MA, Baradaran B.   The alterations of cellular signaling pathways in the host cell upon the high pathogenic Coronaviruses infection, SARS-CoV and MERS-CoV. What could be expected from the SARS-CoV-2? 2020. Available from: https://www.researchgate.net/publication/344729169_The_alterations_of_cellular_signaling_pathways_in_the_host_cell_upon_the_high_pathogenic_Coronaviruses_infection_SARS-CoV_and_MERS-CoV_What_could_be_expected_from_the_SARS-CoV-2.  [PubMed]  [DOI]  [Cited in This Article: ]
15.  Shiri Aghbash P, Eslami N, Shamekh A, Entezari-Maleki T, Bannazadeh Baghi H. SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis. Life Sci. 2021;270:119124.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 61]  [Cited by in F6Publishing: 50]  [Article Influence: 16.7]  [Reference Citation Analysis (0)]
16.  Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020;111:102452.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 554]  [Cited by in F6Publishing: 518]  [Article Influence: 129.5]  [Reference Citation Analysis (0)]
17.  Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324:782-793.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2691]  [Cited by in F6Publishing: 3032]  [Article Influence: 758.0]  [Reference Citation Analysis (0)]
18.  Oroojalian F, Haghbin A, Baradaran B, Hemmat N, Shahbazi MA, Bannazadeh Baghi H, Mokhtarzadeh A, Hamblin MR. Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials. Int J Biol Macromol. 2020;165:18-43.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 31]  [Article Influence: 7.8]  [Reference Citation Analysis (0)]
19.  Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271-280.e8.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11946]  [Cited by in F6Publishing: 13734]  [Article Influence: 3433.5]  [Reference Citation Analysis (0)]
20.  Azer SA. COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes New Infect. 2020;37:100738.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 82]  [Cited by in F6Publishing: 64]  [Article Influence: 16.0]  [Reference Citation Analysis (0)]
21.  Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41:1141-1149.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1433]  [Cited by in F6Publishing: 1358]  [Article Influence: 339.5]  [Reference Citation Analysis (0)]
22.  Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4113]  [Cited by in F6Publishing: 4488]  [Article Influence: 213.7]  [Reference Citation Analysis (0)]
23.  Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021;97:312-320.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 362]  [Cited by in F6Publishing: 373]  [Article Influence: 124.3]  [Reference Citation Analysis (0)]
24.  Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): A Review of Clinical Features, Diagnosis, and Treatment. Cureus. 2020;12:e7355.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 138]  [Cited by in F6Publishing: 146]  [Article Influence: 36.5]  [Reference Citation Analysis (0)]
25.  Ahmad T, Chaudhuri R, Joshi MC, Almatroudi A, Rahmani AH, Ali SM. COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. Front Microbiol. 2020;11:588409.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 16]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
26.  Wu J, Deng W, Li S, Yang X. Advances in research on ACE2 as a receptor for 2019-nCoV. Cell Mol Life Sci. 2021;78:531-544.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 56]  [Cited by in F6Publishing: 42]  [Article Influence: 10.5]  [Reference Citation Analysis (0)]
27.  Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50:620-632.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 313]  [Cited by in F6Publishing: 280]  [Article Influence: 70.0]  [Reference Citation Analysis (0)]
28.  Shiri Aghbash P, Hemmat N, Nahand JS, Shamekh A, Memar MY, Babaei A, Bannazadeh Baghi H. The role of Th17 cells in viral infections. Int Immunopharmacol. 2021;91:107331.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 26]  [Article Influence: 8.7]  [Reference Citation Analysis (0)]
29.  Zhang Y, Geng X, Tan Y, Li Q, Xu C, Xu J, Hao L, Zeng Z, Luo X, Liu F, Wang H. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed Pharmacother. 2020;127:110195.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 160]  [Cited by in F6Publishing: 184]  [Article Influence: 46.0]  [Reference Citation Analysis (0)]
30.  Labbé K, Saleh M. Cell death in the host response to infection. Cell Death Differ. 2008;15:1339-1349.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 264]  [Cited by in F6Publishing: 284]  [Article Influence: 17.8]  [Reference Citation Analysis (0)]
31.  Dhand R, Li J. Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. Am J Respir Crit Care Med. 2020;202:651-659.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 173]  [Cited by in F6Publishing: 197]  [Article Influence: 49.3]  [Reference Citation Analysis (0)]
32.  Noorimotlagh Z, Jaafarzadeh N, Martínez SS, Mirzaee SA. A systematic review of possible airborne transmission of the COVID-19 virus (SARS-CoV-2) in the indoor air environment. Environ Res. 2021;193:110612.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 122]  [Cited by in F6Publishing: 115]  [Article Influence: 38.3]  [Reference Citation Analysis (0)]
33.  Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141-154.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2083]  [Cited by in F6Publishing: 2875]  [Article Influence: 958.3]  [Reference Citation Analysis (0)]
34.  Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1218]  [Cited by in F6Publishing: 1130]  [Article Influence: 282.5]  [Reference Citation Analysis (0)]
35.  Sharma R, Agarwal M, Gupta M, Somendra S, Saxena SK.   Clinical Characteristics and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19). In: Saxena S (eds). Coronavirus Disease 2019 (COVID-19). Medical Virology: From Pathogenesis to Disease Control. Springer, Singapore.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 48]  [Cited by in F6Publishing: 4]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
36.  Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. Physiology (Bethesda). 2020;35:288-301.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 88]  [Cited by in F6Publishing: 136]  [Article Influence: 34.0]  [Reference Citation Analysis (0)]
37.  Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383:2255-2273.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1324]  [Cited by in F6Publishing: 1859]  [Article Influence: 464.8]  [Reference Citation Analysis (0)]
38.  Younan P, Iampietro M, Nishida A, Ramanathan P, Santos RI, Dutta M, Lubaki NM, Koup RA, Katze MG, Bukreyev A. Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm. mBio. 2017;8.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 66]  [Cited by in F6Publishing: 82]  [Article Influence: 11.7]  [Reference Citation Analysis (0)]
39.  Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14113]  [Cited by in F6Publishing: 14503]  [Article Influence: 3625.8]  [Reference Citation Analysis (0)]
40.  Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1881]  [Cited by in F6Publishing: 2835]  [Article Influence: 283.5]  [Reference Citation Analysis (0)]
41.  Ljungberg LU, Zegeye MM, Kardeby C, Fälker K, Repsilber D, Sirsjö A. Global Transcriptional Profiling Reveals Novel Autocrine Functions of Interleukin 6 in Human Vascular Endothelial Cells. Mediators Inflamm. 2020;2020:4623107.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 7]  [Article Influence: 1.8]  [Reference Citation Analysis (1)]
42.  Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121:3375-3383.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 538]  [Cited by in F6Publishing: 541]  [Article Influence: 41.6]  [Reference Citation Analysis (0)]
43.  Moshapa FT, Riches-Suman K, Palmer TM. Therapeutic Targeting of the Proinflammatory IL-6-JAK-STAT Signalling Pathways Responsible for Vascular Restenosis in Type 2 Diabetes Mellitus. Cardiol Res Pract. 2019;2019:9846312.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 46]  [Article Influence: 9.2]  [Reference Citation Analysis (0)]
44.  Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19. Arch Med Res. 2020;51:595-597.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 67]  [Cited by in F6Publishing: 69]  [Article Influence: 17.3]  [Reference Citation Analysis (0)]
45.  Magro G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? Cytokine X. 2020;2:100029.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 135]  [Cited by in F6Publishing: 128]  [Article Influence: 32.0]  [Reference Citation Analysis (0)]
46.  Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA. Cytokine Release Syndrome: Current Perspectives. Immunotargets Ther. 2019;8:43-52.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 80]  [Cited by in F6Publishing: 99]  [Article Influence: 19.8]  [Reference Citation Analysis (0)]
47.  Kahn R, Schmidt T, Golestani K, Mossberg A, Gullstrand B, Bengtsson AA, Kahn F. Mismatch between circulating cytokines and spontaneous cytokine production by leukocytes in hyperinflammatory COVID-19. J Leukoc Biol. 2021;109:115-120.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 20]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
48.  Pomponio G, Ferrarini A, Bonifazi M, Moretti M, Salvi A, Giacometti A, Tavio M, Titolo G, Morbidoni L, Frausini G, Onesta M, Amico D, Rocchi MLB, Menzo S, Zuccatosta L, Mei F, Menditto V, Svegliati S, Donati A, D'Errico MM, Pavani M, Gabrielli A. Tocilizumab in COVID-19 interstitial pneumonia. J Intern Med. 2021;289:738-746.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 9]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
49.  Heo TH, Wahler J, Suh N. Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. Oncotarget. 2016;7:15460-15473.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 76]  [Cited by in F6Publishing: 80]  [Article Influence: 11.4]  [Reference Citation Analysis (0)]
50.  Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre E, De Luca G, Farina N, Boffini N, Ruggeri A, Poli A, Scarpellini P, Rovere-Querini P, Tresoldi M, Salonia A, Montorsi F, Landoni G, Castagna A, Ciceri F, Zangrillo A, Dagna L. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021;3:e253-e261.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 85]  [Cited by in F6Publishing: 121]  [Article Influence: 40.3]  [Reference Citation Analysis (0)]
51.  Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, Marcos-Jiménez A, Sánchez-Alonso S, Fernández-Díaz C, Alcaraz-Serna A, Mateu-Albero T, Rodríguez-Cortes P, Sánchez-Cerrillo I, Esparcia L, Martínez-Fleta P, López-Sanz C, Gabrie L, Del Campo Guerola L, Suárez-Fernández C, Ancochea J, Canabal A, Albert P, Rodríguez-Serrano DA, Aguilar JM, Del Arco C, de Los Santos I, García-Fraile L, de la Cámara R, Serra JM, Ramírez E, Alonso T, Landete P, Soriano JB, Martín-Gayo E, Fraile Torres A, Zurita Cruz ND, García-Vicuña R, Cardeñoso L, Sánchez-Madrid F, Alfranca A, Muñoz-Calleja C, González-Álvaro I; REINMUN-COVID Group. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study. J Allergy Clin Immunol. 2021;147:72-80.e8.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 98]  [Cited by in F6Publishing: 145]  [Article Influence: 36.3]  [Reference Citation Analysis (0)]
52.  Soto GP. Potential therapeutic agents against COVID-19 based on blocking and inhibition of the viral life cycle and the cytokine storm syndrome. An Fac Cienc Méd (Asunción). 2020;53:131-146.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 1]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
53.  Huang E, Isonaka S, Yang H, Salce E, Rosales E, Jordan SC. Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study. Int J Infect Dis. 2021;105:245-251.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 10]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
54.  Deana C, Vetrugno L, Bassi F, De Monte A. Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline? Med Mycol Case Rep. 2021;31:32-34.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 10]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
55.  Setliff E, Kosmisky D, Ngeve R. 683: Necrotizing Fasciitis and Candidemia After Tocilizumab Initiation: A Case Report. Crit Care Med. 2021;49:336.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 1]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
56.  Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella G, Converso M, Cozzi M, Crosasso P, De Iaco F, Di Perri G, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, Rossi D. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19. Clin Exp Rheumatol. 2020;38:529-532.  [PubMed]  [DOI]  [Cited in This Article: ]
57.  Mazzitelli M, Arrighi E, Serapide F, Pelle MC, Tassone B, Lionello R, Marrazzo G, Laganà D, Costanzo FS, Matera G, Trecarichi EM, Torti C. Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia. J Med Virol. 2021;93:32-34.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 22]  [Cited by in F6Publishing: 26]  [Article Influence: 6.5]  [Reference Citation Analysis (0)]
58.  Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med. 2020;18:405.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 72]  [Cited by in F6Publishing: 79]  [Article Influence: 19.8]  [Reference Citation Analysis (0)]
59.  Masiá M, Fernández-González M, Padilla S, Ortega P, García JA, Agulló V, García-Abellán J, Telenti G, Guillén L, Gutiérrez F. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study. EBioMedicine. 2020;60:102999.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 62]  [Cited by in F6Publishing: 62]  [Article Influence: 15.5]  [Reference Citation Analysis (0)]
60.  Ponthieux F, Dauby N, Maillart E, Fils JF, Smet J, Claus M, Besse-Hammer T, Bels D, Corazza F, Nagant C. Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6. Viral Immunol. 2022;35:60-70.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 2]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
61.  Chan KH, Patel B, Podel B, Szablea ME, Shaaban HS, Guron G, Slim J. Tocilizumab and Thromboembolism in COVID-19: A Retrospective Hospital-Based Cohort Analysis. Cureus. 2021;13:e15208.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 6]  [Reference Citation Analysis (0)]
62.  Al-Baadani A, Eltayeb N, Alsufyani E, Albahrani S, Basheri S, Albayat H, Batubara E, Ballool S, Al Assiri A, Faqihi F, Musa AB, Robert AA, Alsherbeeni N, Elzein F. Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes. J Infect Public Health. 2021;14:1021-1027.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 6]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
63.  Kow CS, Hasan SS. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2021;77:1089-1094.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 20]  [Article Influence: 6.7]  [Reference Citation Analysis (0)]
64.  Moreno Diaz R, Amor García MA, Teigell Muñoz FJ, Saldaña Perez LE, Mateos Gonzalez M, Melero Bermejo JA, López Hernández A, Reyes Marquez L, De Guzman García-Monge MT, Perez Quero JL, Homez Guzman MP. Does timing matter on tocilizumab administration? Eur J Hosp Pharm. 2021;.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9]  [Cited by in F6Publishing: 9]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
65.  Eşkazan AE, Balkan İİ, Demirbaş KC, Ar MC, Karaali R, Sekibağ Y, Mulamahmutoğlu S, Yartaş Dumanlı G, Çakmak F, Özgür Yurttaş N, Kurt F, Aladağ Kurt S, Kuşkucu M, Ürkmez S, Börekçi Ş, Saribal D, Mete B, Bavunoğlu I, Dikmen Y, Aygün G, Midilli K, Tabak F. Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score. J Infect Chemother. 2021;27:1329-1335.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 7]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
66.  Li P, Lu Z, Li Q, Wang Z, Guo Y, Cai C, Wang S, Liu P, Su X, Huang Y, Dong Y, Qiu W, Ling Y, Yarmus L, Luo F, Zeng L, Bai C, Zhang W. Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6. Front Mol Biosci. 2021;8:651662.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 7]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
67.  RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637-1645.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 946]  [Cited by in F6Publishing: 948]  [Article Influence: 316.0]  [Reference Citation Analysis (0)]
68.  Van den Eynde E, Gasch O, Oliva JC, Prieto E, Calzado S, Gomila A, Machado ML, Falgueras L, Ortonobes S, Morón A, Capilla S, Navarro G, Oristrell J, Cervantes M, Navarro M. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital. Infect Dis (Lond). 2021;53:291-302.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 16]  [Article Influence: 5.3]  [Reference Citation Analysis (0)]
69.   Efficacy of Early Administration of Tocilizumab in COVID-19 Patients - American College of Cardiology. [cited March 28, 2021] Available from: https://www.acc.org/Latest-in-cardiology/clinical-trials/2020/12/31/20/42/rct-tcz-covid-19.  [PubMed]  [DOI]  [Cited in This Article: ]
70.  Akinosoglou K, Velissaris D, Ziazias D, Davoulos C, Tousis A, Tsiotsios K, Kalogeropoulou C, Spyridonidis A, Marangos M, Fligkou F, Gogos C. Remdesivir and tocilizumab: Mix or match. J Med Virol. 2021;93:56-58.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 7]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
71.  Antony SJ, Davis MA, Davis MG, Almaghlouth NK, Guevara R, Omar F, Del Rey F, Hassan A, Arian MU, Antony N, Prakash BV. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management. J Med Virol. 2021;93:491-498.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 15]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
72.  Bhandari S, Rankawat G, Singh A. Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients. Indian J Crit Care Med. 2021;25:260-266.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 5]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
73.  Chilimuri S, Sun H, Alemam A, Kang KS, Lao P, Mantri N, Schiller L, Sharabun M, Shehi E, Tejada J, Yugay A, Nayudu SK. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study. J Clin Pharm Ther. 2021;46:440-446.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9]  [Cited by in F6Publishing: 12]  [Article Influence: 3.0]  [Reference Citation Analysis (2)]
74.  REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettilä V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;384:1491-1502.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1175]  [Cited by in F6Publishing: 1239]  [Article Influence: 413.0]  [Reference Citation Analysis (0)]
75.  Furlow B. COVACTA trial raises questions about tocilizumab's benefit in COVID-19. Lancet Rheumatol. 2020;2:e592.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 86]  [Cited by in F6Publishing: 90]  [Article Influence: 22.5]  [Reference Citation Analysis (0)]
76.  Hasanin A, Mostafa M. Tocilizumab in patients with COVID-19: which patient, time, and dose? J Anesth. 2021;35:896-902.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 4]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
77.  Satarker S, Tom AA, Shaji RA, Alosious A, Luvis M, Nampoothiri M. JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy. Postgrad Med. 2021;133:489-507.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 91]  [Cited by in F6Publishing: 91]  [Article Influence: 30.3]  [Reference Citation Analysis (0)]
78.  Novartis  Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19. [cited March 20, 2021] Available from: https://www.novartis.com/news/media-releases/novartis-provides-update-ruxcovid-study-ruxolitinib-hospitalized-patients-covid-19.  [PubMed]  [DOI]  [Cited in This Article: ]
79.  Eli Lilly and Company  Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial. [cited March 20, 2021]. Available from: https://investor.lilly.com/news-releases/news-release-details/baricitinib-combination-remdesivir-reduces-time-recovery.  [PubMed]  [DOI]  [Cited in This Article: ]
80.  Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021;384:795-807.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1159]  [Cited by in F6Publishing: 1260]  [Article Influence: 420.0]  [Reference Citation Analysis (1)]
81.  Mortara A, Mazzetti S, Margonato D, Delfino P, Bersano C, Catagnano F, Lauriola M, Grosso P, Perseghin G, Ippoliti G. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation. Clin Transl Sci. 2021;14:1062-1068.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 8]  [Article Influence: 2.7]  [Reference Citation Analysis (0)]
82.  Kaplanski G, Bontemps D, Esnault P, Blasco V, Carvelli J, Delarbre D, Cauchois R, Forel JM, Papazian L. Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study. Autoimmun Rev. 2021;20:102726.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 13]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
83.  Maslennikov R, Ivashkin V, Vasilieva E, Chipurik M, Semikova P, Semenets V, Russkova T, Levshina A, Grigoriadis D, Magomedov S, Efremova I, Dzhakhaya N. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19. Pulm Pharmacol Ther. 2021;69:102039.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 31]  [Article Influence: 10.3]  [Reference Citation Analysis (1)]
84.  Rieder M, Wengenmayer T, Staudacher D, Duerschmied D, Supady A. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation. Crit Care. 2020;24:435.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 45]  [Cited by in F6Publishing: 41]  [Article Influence: 10.3]  [Reference Citation Analysis (0)]
85.  Supady A, Duerschmied D, Bode C, Rieder M, Lother A. Extracorporeal cytokine adsorption as an alternative to pharmacological inhibition of IL-6 in COVID-19. Crit Care. 2020;24:514.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 5]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
86.  Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53:368-370.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 523]  [Cited by in F6Publishing: 571]  [Article Influence: 142.8]  [Reference Citation Analysis (0)]
87.  Bulat V, Situm M, Azdajic MD, Likic R. Potential role of IL-17 blocking agents in the treatment of severe COVID-19? Br J Clin Pharmacol. 2021;87:1578-1581.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 37]  [Article Influence: 9.3]  [Reference Citation Analysis (0)]
88.  Martonik D, Parfieniuk-Kowerda A, Rogalska M, Flisiak R. The Role of Th17 Response in COVID-19. Cells. 2021;10.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 29]  [Cited by in F6Publishing: 83]  [Article Influence: 27.7]  [Reference Citation Analysis (1)]
89.  Liu P, Huang Z, Yin M, Liu C, Chen X, Pan P, Kuang Y. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial. Trials. 2020;21:999.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 9]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
90.  Carugno A, Gambini DM, Raponi F, Vezzoli P, Robustelli Test E, Arosio MEG, Callegaro A, Sena P. Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: Is there a role for Interleukin 17? Dermatol Ther. 2020;33:e14011.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 10]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
91.  Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861-880.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1199]  [Cited by in F6Publishing: 1190]  [Article Influence: 396.7]  [Reference Citation Analysis (0)]
92.  Hasan MJ, Rabbani R, Anam AM, Huq SMR. Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact? J Infect. 2021;83:e11-e13.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 4]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
93.  National Library of Medicine  DailyMed - KEVZARA- sarilumab injection, solution. [cited March 20, 2021] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=827bc01c-d379-4266-a18c-c7f904b76af3.  [PubMed]  [DOI]  [Cited in This Article: ]
94.  National Library of Medicine  DailyMed - ACTEMRA- tocilizumab injection, solution, concentrate ACTEMRA- tocilizumab injection, solution ACTEMRA ACTPEN- tocilizumab injection, solution. [cited March 20, 2021] Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13.  [PubMed]  [DOI]  [Cited in This Article: ]
95.  Charan J, Dutta S, Kaur R, Bhardwaj P, Sharma P, Ambwani S, Jahan I, Abubakar AR, Islam S, Hardcastle TC, Rahman NAA, Lugova H, Haque M. Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. Expert Opin Drug Saf. 2021;20:1125-1136.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 8]  [Article Influence: 2.7]  [Reference Citation Analysis (0)]
96.  National Library of Medicine  DailyMed - SYLVANT- siltuximab injection, powder, for solution. [cited March 20, 2021] Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d663642-f52e-49c0-a023-2da083fdfc0b.  [PubMed]  [DOI]  [Cited in This Article: ]
97.  National Library of Medicine  DailyMed - OLUMIANT- baricitinib tablet, film coated. [cited March 20, 2021] Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf#s21.  [PubMed]  [DOI]  [Cited in This Article: ]
98.  Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, Höper H, Volk V, Mishra N, Blase JI, Nikolaus S, Bethge J, Kühbacher T, Röcken C, Chen M, Cottingham I, Petri N, Rasmussen BB, Lokau J, Lenk L, Garbers C, Feuerhake F, Rose-John S, Waetzig GH, Rosenstiel P. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease. Gastroenterology. 2021;160:2354-2366.e11.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 61]  [Cited by in F6Publishing: 132]  [Article Influence: 44.0]  [Reference Citation Analysis (0)]
99.  National Library of Medicine  DailyMed - JAKAFI- ruxolitinib tablet. [cited March 20, 2021] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b.  [PubMed]  [DOI]  [Cited in This Article: ]
100.  Chachar AZK, Khan KA, Iqbal J, Shahid AH, Asif M, Fatima SA, Khan AA, Younis BB. "Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience", a retrospective study-original article. Ann Med Surg (Lond). 2021;63:102165.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 6]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
101.  Riggs K, Patel V, Pittiglio M, Cavanaugh J, Sullivan J. 309: Evaluation of the Efficacy of Tocilizumab in Critically Ill COVID-19 Patients. Crit Care Med. 2021;49:141.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 1]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
102.  Adıyeke E, Coşkun N, Bakan N, Demir S, Cihan M, Yiyit N. Efficacy of Tocilizumab in the treatment of severe COVID-19 patients with respiratory failure. Med Sci Discov. 2021;8:86-90.  [PubMed]  [DOI]  [Cited in This Article: ]
103.  Chen Y, Zhang X.   Preliminary Efficacy of Tocilizumab Treatment in The Patients With COVID-19. 2021.  [PubMed]  [DOI]  [Cited in This Article: ]
104.  Amin S, Rahim F, Bahadur S, Noor M, Mahmood A, Gul H. The Effect of Tocilizumab on Inflammatory Markers in Survivors and Non-survivors of Severe COVID-19. J Coll Physicians Surg Pak. 2021;31:S7-S10.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 4]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
105.  Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turrà C, Ballerini PF, Sciascia R, Zammarchi L, Para O, Scotton PG, Inojosa WO, Ravagnani V, Salerno ND, Sainaghi PP, Brignone A, Codeluppi M, Teopompi E, Milesi M, Bertomoro P, Claudio N, Salio M, Falcone M, Cenderello G, Donghi L, Del Bono V, Colombelli PL, Angheben A, Passaro A, Secondo G, Pascale R, Piazza I, Facciolongo N, Costantini M; RCT-TCZ-COVID-19 Study Group. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021;181:24-31.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 474]  [Cited by in F6Publishing: 511]  [Article Influence: 170.3]  [Reference Citation Analysis (0)]
106.  Wang D, Fu B, Peng Z, Yang D, Han M, Li M, Yang Y, Yang T, Sun L, Li W.   Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial. 2020.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 8]  [Reference Citation Analysis (0)]
107.  Sanofi  Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. (cited March 28, 2021). https://www.sanofi.com/en/media-room/press-releases/2020/2020-09-01-07-00-00.  [PubMed]  [DOI]  [Cited in This Article: ]
108.  Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, Patel N, Hagino O.   Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. MedRxiv 2021.  [PubMed]  [DOI]  [Cited in This Article: ]
109.  Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, Skiest D, Aziz MS, Cooper N, Douglas IS, Savic S, Youngstein T, Del Sorbo L, Cubillo Gracian A, De La Zerda DJ, Ustianowski A, Bao M, Dimonaco S, Graham E, Matharu B, Spotswood H, Tsai L, Malhotra A. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021;384:1503-1516.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 661]  [Cited by in F6Publishing: 676]  [Article Influence: 225.3]  [Reference Citation Analysis (0)]
110.  Flisiak R, Jaroszewicz J, Rogalska M, Łapiński T, Berkan-Kawińska A, Bolewska B, Tudrujek-Zdunek M, Kozielewicz D, Rorat M, Leszczyński P. Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. J Clin Med. 2021;10.  [PubMed]  [DOI]  [Cited in This Article: ]
111.  Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, Patel N, Hagino O; Sarilumab COVID-19 Global Study Group. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9:522-532.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 133]  [Cited by in F6Publishing: 160]  [Article Influence: 53.3]  [Reference Citation Analysis (0)]
112.  Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, Woolley AE, Nikiforow S, Lin N, Sagar M, Schrager H, Huckins DS, Axelrod M, Pincus MD, Fleisher J, Sacks CA, Dougan M, North CM, Halvorsen YD, Thurber TK, Dagher Z, Scherer A, Wallwork RS, Kim AY, Schoenfeld S, Sen P, Neilan TG, Perugino CA, Unizony SH, Collier DS, Matza MA, Yinh JM, Bowman KA, Meyerowitz E, Zafar A, Drobni ZD, Bolster MB, Kohler M, D'Silva KM, Dau J, Lockwood MM, Cubbison C, Weber BN, Mansour MK; BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020;383:2333-2344.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 998]  [Cited by in F6Publishing: 982]  [Article Influence: 245.5]  [Reference Citation Analysis (0)]